NASDAQ
DCPH

Deciphera Pharmaceuticals LLC

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Deciphera Pharmaceuticals LLC Stock Price

Vitals

Today's Low:
$13.47
Today's High:
$13.75
Open Price:
$13.74
52W Low:
$10.14
52W High:
$22.76
Prev. Close:
$13.7
Volume:
346550

Company Statistics

Market Cap.:
$1.13 billion
Book Value:
5.606
Revenue TTM:
$138.26 million
Operating Margin TTM:
-136.76%
Gross Profit TTM:
$-62555000
Profit Margin:
-131.38%
Return on Assets TTM:
-25.29%
Return on Equity TTM:
-51.05%

Company Profile

Deciphera Pharmaceuticals LLC had its IPO on 2017-09-28 under the ticker symbol DCPH.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Deciphera Pharmaceuticals LLC has a staff strength of 300 employees.

Stock update

Shares of Deciphera Pharmaceuticals LLC opened at $13.74 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $13.47 - $13.75, and closed at $13.54.

This is a -1.17% slip from the previous day's closing price.

A total volume of 346,550 shares were traded at the close of the day’s session.

In the last one week, shares of Deciphera Pharmaceuticals LLC have slipped by -6.88%.

Deciphera Pharmaceuticals LLC's Key Ratios

Deciphera Pharmaceuticals LLC has a market cap of $1.13 billion, indicating a price to book ratio of 2.7336 and a price to sales ratio of 8.7041.

In the last 12-months Deciphera Pharmaceuticals LLC’s revenue was $138.26 million with a gross profit of $-62555000 and an EBITDA of $-186316000. The EBITDA ratio measures Deciphera Pharmaceuticals LLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Deciphera Pharmaceuticals LLC’s operating margin was -136.76% while its return on assets stood at -25.29% with a return of equity of -51.05%.

In Q1, Deciphera Pharmaceuticals LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 14.4%.

Deciphera Pharmaceuticals LLC’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Deciphera Pharmaceuticals LLC’s profitability.

Deciphera Pharmaceuticals LLC stock is trading at a EV to sales ratio of 5.6366 and a EV to EBITDA ratio of -3.1127. Its price to sales ratio in the trailing 12-months stood at 8.7041.

Deciphera Pharmaceuticals LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$549.02 million
Total Liabilities
$83.91 million
Operating Cash Flow
$-35414000.00
Capital Expenditure
$360000
Dividend Payout Ratio
0%

Deciphera Pharmaceuticals LLC ended 2024 with $549.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $549.02 million while shareholder equity stood at $440.08 million.

Deciphera Pharmaceuticals LLC ended 2024 with $0 in deferred long-term liabilities, $83.91 million in other current liabilities, 785000.00 in common stock, $-1282972000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $114.64 million and cash and short-term investments were $398.63 million. The company’s total short-term debt was $3,301,000 while long-term debt stood at $0.

Deciphera Pharmaceuticals LLC’s total current assets stands at $476.16 million while long-term investments were $27.63 million and short-term investments were $284.00 million. Its net receivables were $22.44 million compared to accounts payable of $19.67 million and inventory worth $25.53 million.

In 2024, Deciphera Pharmaceuticals LLC's operating cash flow was $-35414000.00 while its capital expenditure stood at $360000.

Comparatively, Deciphera Pharmaceuticals LLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$13.54
52-Week High
$22.76
52-Week Low
$10.14
Analyst Target Price
$21.33

Deciphera Pharmaceuticals LLC stock is currently trading at $13.54 per share. It touched a 52-week high of $22.76 and a 52-week low of $22.76. Analysts tracking the stock have a 12-month average target price of $21.33.

Its 50-day moving average was $13.96 and 200-day moving average was $15.12 The short ratio stood at 6.61 indicating a short percent outstanding of 0%.

Around 2998.7% of the company’s stock are held by insiders while 7308.7% are held by institutions.

Frequently Asked Questions About Deciphera Pharmaceuticals LLC

The stock symbol (also called stock or share ticker) of Deciphera Pharmaceuticals LLC is DCPH

The IPO of Deciphera Pharmaceuticals LLC took place on 2017-09-28

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$39.83
-1.81
-4.35%
$1715
-80.5
-4.48%
SoftBank Corp (SFBQF)
$11.53
-0.28
-2.34%
$23.76
0
0%
$216.77
1.44
+0.67%
$31.47
0.54
+1.75%
$10.85
0.02
+0.18%
$23.35
0.07
+0.3%
$2889.5
-154
-5.06%
$40
-1.91
-4.56%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 in combination with RTK/RAS/MAP kinase signaling pathway inhibition to treat RAS/RAF mutant cancers. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Address

200 Smith Street, Waltham, MA, United States, 02451